Role of miR200b-5p miRNA in lymphomagenesis associated with Sjögren’s syndrome (SS)

Efstathia K. Kapsogeorgou, Athanasios G. Tzioufas

Mediterr J Rheumatol 2018; 29(1):56-8
Role of miR200b-5p miRNA in lymphomagenesis associated with Sjögren’s syndrome (SS)

Efstathia K. Kapsogeorgou, Athanasios G. Tzioufas

Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Greece

ABSTRACT

Background: Development of non-Hodgkin’s lymphoma (NHL) is the major adverse outcome of primary Sjögren’s Syndrome (pSS) affecting both morbidity and mortality. The high frequency of transformation to lymphoid malignancy in pSS among autoimmune rheumatic diseases (6-10% of patients) and the accessibility of the affected organ (minor salivary glands; MSG), render pSS an ideal model for the study of lymphomagenesis associated with autoimmune diseases and inflammation. Although pSS-related lymphoid transformation is generally considered as an antigen-driven, multi-step process owed to the chronic activation of B-cells in MSGs, the underlying mechanisms remain elusive. Our recent results support that miR200b-5p miRNA is significantly down-regulated in the MSGs of pSS patients who have or will develop lymphoma, long before lymphoma clinical onset, indicating that it may be involved in lymphomagenesis. Aim: To investigate the role of miR200b-5p miRNA in pSS-associated lymphomagenesis. Methods: At first, the miR200b-5p-expression will be examined by in situ hybridization in MSGs of pSS patients who are at low risk and have not developed NHL during follow-up, high risk and developed NHL in the future (pre-lymphoma) or have NHL, and the expressing cellular types, as well as those with reduced expression during lymphomagenesis, will be identified. Then, the miR200b-5p targeted molecular pathways in those cellular types (epithelial, B-cells and/or other lymphocytes, all non-neoplastic) will be studied in in vitro experiments by over-expressing and silencing of miR200b-5p, followed by transcriptome analysis. This approach is expected to find possibly novel pathogenetic mechanisms underlying SS-related lymphomagenesis. The latter is of high significance, not only for the understanding of lymphomagenesis, but also for its reversal and/or treatment. Anticipated Benefits: This approach is anticipated to a) reveal the differentially regulated molecules and pathways by miR200b-5p, b) enlighten novel pathogenetic pathways underlying lymphomagenesis and c) identify novel therapeutic targets and possibly evidence-based therapeutic interventions.

BACKGROUND/INTRODUCTION

The development of B-cell non-Hodgkin lymphoma (NHL) is common in primary Sjögren’s syndrome (pSS) (6-10% of patients) and affects both morbidity and mortality. In the majority of pSS patients, NHL starts in the exocrine glands, such as the salivary glands, which are the major target of pSS autoimmune responses. The high frequency of transformation to lymphoid malignan-
miRNAs, mainly miR200b-3p, are thought central regulators of oncogenesis, tumor metastasis and drug resistance of solid tumors by regulating epithelial-to-mesenchymal transition (EMT) primarily by down-regulation of the zinc-finger E-box-binding homeobox-1 (ZEB1) transcription factor and AKT activation.\textsuperscript{24,25} Furthermore, elevated miR200b expression and subsequent inhibition of ZEB1 transcription factor and increased BCL6 protein expression has been associated with better prognosis of the Helicobacter pylori-positive gastric diffuse large B-cell lymphomas, compared to Helicobacter pylori-negative ones.\textsuperscript{26}

**AIM OF THE STUDY**

Our findings support the implication of miR200b-5p miRNA in the lymphomagenesis in pSS. In this study, we propose the dissection of its role by identifying the expressing cells and the regulated molecular pathways.

**RESEARCH PLAN – METHODS**

The cells expressing miR200b-5p in the MSG tissues, as well as those with reduced expression in MSGs from pre-lymphoma and lymphoma pSS patients, will be identified by in situ hybridization (ISH) using commercially available LNA-probes (Exiqon). Subsequently, the function of miR200b-5p in these cell types (SGEC, B, T and/or other type of lymphocytes) will be interrogated using specific miRNA inhibitors and mimics, respectively, followed by transcriptome analysis for the identification of the regulated genes and pathways. Finally, the pathogenetic potential of the identified pathways in the lymphomagenesis of pSS will be verified by investigating the expression of the molecules comprising the pathway in MSG tissues, SGECs and B cells from pSS patients with lymphoma or not. The expression of these molecules will be performed at the mRNA level by qPCR and at the protein level by immunohistochemistry in MSG tissues and/or immunoblotting and flow cytometry in cultured non-neoplastic cells (SGECs, B, T and/or other type of lymphocytes isolated from the peripheral blood of healthy donors).

The proposed study has been approved by the Ethics Committee of School of Medicine, NKUA, Greece (Protocol-No.: 1516023881).

**IMPACT OF THE STUDY**

The study is expected to a) reveal the differentially regulated molecules and pathways by miR200b-5p, b) enlighten novel pathogenetic pathways with therapeutic potential and c) facilitate the better understanding of the mechanisms underlying lymphomagenesis in pSS, which is mandatory for the discovery of novel therapeutic targets and/or the evidence-based therapeutic administration of existing agents. The study of the pathogenet-
ic mechanisms underlying progression to lymphoma in pSS is mandatory, since it may facilitate the arrest of the progression to and/or the effective treatment of malignancy in pSS, as well as other lymphoid malignancies, as suggested by the low MSG expression of miR200b-5p in a patient with HBV-sialadenitis and MALT lymphoma (our unpublished data).

CONFLICT OF INTEREST
The authors declare no conflict of interest.

REFERENCES
22. Gourzi VC, Kapsogeorgou EK, Kyrkikidis NC, Tzioufas AG. Study of microRNAs (miRNAs) that are predicted to target the autoantigens Ro/SSA and La/SSB in primary Sjogren’s Syndrome. Clin Exp Immunol 2015;182:14-22.